Immune cells and STAT3-mediated inflammation in calcific aortic valve disease
钙化性主动脉瓣疾病中的免疫细胞和 STAT3 介导的炎症
基本信息
- 批准号:9907624
- 负责人:
- 金额:$ 2.18万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-02-01 至 2020-09-30
- 项目状态:已结题
- 来源:
- 关键词:Adaptive Immune SystemAlgorithmsAntigensAntimetabolitesAortic Valve StenosisB-LymphocytesBasic ScienceBiological AssayBiologyBone MarrowBone Marrow TransplantationCD4 Positive T LymphocytesCardiovascular DiseasesCardiovascular systemCell ProliferationCell physiologyCellsCessation of lifeCharacteristicsClinicalCoculture TechniquesComputerized Medical RecordCoxibsCytokine SignalingDataDatabasesDiabetes MellitusDiagnosticDiseaseDyslipidemiasDystrophic CalcificationEndothelial CellsEndotheliumFibrosisFoundationsFunctional disorderGeneticHeart failureHematopoieticHumanHypertensionImmuneImmune responseImmunologicsImmunosuppressionIn VitroInfiltrationInflammationInflammatoryInflammatory ResponseInterleukin 6 ReceptorInterleukin-6InvestigationKnock-outKnowledgeLeadLymphocyteLymphocyte ActivationMature T-LymphocyteMechanicsMediatingMethotrexateModelingModificationMorbidity - disease rateNatural Language ProcessingNoduleOutcomePathogenesisPathologyPathway interactionsPatientsPharmaceutical PreparationsPharmacological TreatmentPharmacologyPhenotypePhosphorylationPhysiciansPlayPrevalenceProcessProteomicsRag1 MouseRegression AnalysisRiskRisk FactorsRoleSTAT3 geneSamplingScientific Advances and AccomplishmentsScientistSignal TransductionSmokingSpecimenStimulusT-LymphocyteTestingTrainingTranscriptTranslatingTumor-infiltrating immune cellsUnited StatesWorkaortic valveaortic valve disorderaortic valve replacementbicuspid aortic valvecalcificationcelecoxibclinical translationcyclooxygenase 2cytokinehuman diseaseimprovedin vitro Modelin vivoinhibitor/antagonistinterstitial cellknowledge basemacrophagemortalitymouse modelprotective effectresponsetargeted treatmenttheoriestranscription factortranscriptomics
项目摘要
PROJECT SUMMARY
Aortic valve disease is the third most common cardiovascular disease in the United States. Calcific aortic valve
disease (CAVD) is by far the most common cause, yet it has no effective pharmacologic therapy. Currently, all
theories of pathophysiology focus on the contribution of resident aortic valve interstitial and endothelial cells
(AVICs and AVECs respectively). However, macrophages make up a significant fraction of the native aortic
valve, and pathology studies and unbiased transcriptomics of the calcified aortic valve have observed
enrichment of macrophages and T and B lymphocytes. In addition, transcription factor STAT3 and its key
activator IL-6 –both markers of Th17 inflammation – have been found to be increased in in vitro and in vivo
calcification. Recognizing the interplay of immune cell function with endothelial and cardiovascular biology, we
have begun to investigate the contribution of immune cells to CAVD pathophysiology. Our in vitro studies of
STAT3 blockade show an abrogation of mechanical and transcript-level characteristics of dystrophic
calcification. In addition, culture of aortic valve cells with macrophages augments the calcification phenotype.
This background information and preliminary data suggest a mechanism for immune cell contribution to the
pathophysiology of CAVD. Specifically, we suspect that known calcification stimuli induce an inflammatory
phenotype in hematopoietic cells, leading to T lymphocyte infiltration and STAT3-dependent calcific nodule
formation. In Aim 1 we will utilize bone marrow transplants and inhibition of lymphocyte maturation via Rag1
knockout to test the role of hematopoietic cells on the whole and lymphocytes, respectively, in the Notch1+/-
mouse model of CAVD. To test the impact of in vitro models of calcification on immune cells, in Aim 2 we will
utilize in vitro co-culture models of AVICs and macrophages, and probe the effects on STAT3 signaling and
AVIC calcification. Aim 2 will interrogate both the calcification outcomes of valvular cells and the immunological
outcomes of macrophages. To test the clinical translation of this model, in Aim 3 we will assess the
progression of aortic stenosis in patients taking methotrexate, a drug that inhibits T lymphocyte maturation and
thus adaptive immune system activity. With these investigations, this project will (a) be the first to
mechanistically assess the impact of immune cells in CAVD, (b) contribute directly to the clinical knowledge
base on aortic valve disease, and (c) advance the basic science understanding of immune cell physiology
under mechanical strain. Finally, this project will not only advance scientific knowledge on aortic valve disease,
but further serve as the foundation of my training to be an independent physician-scientist.
项目摘要
主动脉瓣疾病是美国第三大常见的心血管疾病。钙化性主动脉瓣
疾病(CAVD)是迄今为止最常见的原因,但它没有有效的药物治疗。目前所有
病理生理学的理论集中在主动脉瓣间质细胞和内皮细胞的贡献上
(分别为AVIC和AVEC)。然而,巨噬细胞占天然主动脉的很大一部分
瓣膜,病理学研究和钙化主动脉瓣的无偏转录组学观察到
富集巨噬细胞和T和B淋巴细胞。此外,转录因子STAT 3及其关键基因
已经发现活化剂IL-6 --Th 17炎症的两种标志物--在体外和体内增加
钙化认识到免疫细胞功能与内皮和心血管生物学的相互作用,我们
已经开始研究免疫细胞对CAVD病理生理学的贡献。我们的体外研究
STAT 3阻断显示了营养不良的机械和转录水平特征的废除。
钙化此外,培养主动脉瓣细胞与巨噬细胞增加钙化表型。
这些背景信息和初步数据表明免疫细胞对免疫系统的作用机制。
CAVD的病理生理学具体地说,我们怀疑已知的钙化刺激会诱导炎症反应。
造血细胞表型,导致T淋巴细胞浸润和STAT 3依赖性钙化结节
阵在目标1中,我们将利用骨髓移植和通过Rag 1抑制淋巴细胞成熟
敲除以分别测试整体造血细胞和淋巴细胞在Notch 1 +/-中的作用
CAVD小鼠模型。为了测试体外钙化模型对免疫细胞的影响,在目标2中,我们将
利用AVIC和巨噬细胞的体外共培养模型,并探测对STAT 3信号传导的影响,
AVIC钙化。目的2将询问瓣膜细胞的钙化结果和免疫学结果。
巨噬细胞的结果。为了测试该模型的临床转化,在目标3中,我们将评估
服用甲氨蝶呤(一种抑制T淋巴细胞成熟的药物)的患者的主动脉瓣狭窄进展,
从而获得适应性免疫系统活性。通过这些调查,该项目将(a)成为第一个
机械地评估免疫细胞在CAVD中的影响,(B)直接有助于临床知识
基于主动脉瓣疾病,和(c)推进免疫细胞生理学的基础科学理解
在机械应力下。最后,该项目不仅将促进对主动脉瓣疾病的科学认识,
但也进一步成为我成为一名独立的物理学家和科学家的基础。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Michael Aston Raddatz其他文献
Michael Aston Raddatz的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
DMS-EPSRC: Asymptotic Analysis of Online Training Algorithms in Machine Learning: Recurrent, Graphical, and Deep Neural Networks
DMS-EPSRC:机器学习中在线训练算法的渐近分析:循环、图形和深度神经网络
- 批准号:
EP/Y029089/1 - 财政年份:2024
- 资助金额:
$ 2.18万 - 项目类别:
Research Grant
CAREER: Blessing of Nonconvexity in Machine Learning - Landscape Analysis and Efficient Algorithms
职业:机器学习中非凸性的祝福 - 景观分析和高效算法
- 批准号:
2337776 - 财政年份:2024
- 资助金额:
$ 2.18万 - 项目类别:
Continuing Grant
CAREER: From Dynamic Algorithms to Fast Optimization and Back
职业:从动态算法到快速优化并返回
- 批准号:
2338816 - 财政年份:2024
- 资助金额:
$ 2.18万 - 项目类别:
Continuing Grant
CAREER: Structured Minimax Optimization: Theory, Algorithms, and Applications in Robust Learning
职业:结构化极小极大优化:稳健学习中的理论、算法和应用
- 批准号:
2338846 - 财政年份:2024
- 资助金额:
$ 2.18万 - 项目类别:
Continuing Grant
CRII: SaTC: Reliable Hardware Architectures Against Side-Channel Attacks for Post-Quantum Cryptographic Algorithms
CRII:SaTC:针对后量子密码算法的侧通道攻击的可靠硬件架构
- 批准号:
2348261 - 财政年份:2024
- 资助金额:
$ 2.18万 - 项目类别:
Standard Grant
CRII: AF: The Impact of Knowledge on the Performance of Distributed Algorithms
CRII:AF:知识对分布式算法性能的影响
- 批准号:
2348346 - 财政年份:2024
- 资助金额:
$ 2.18万 - 项目类别:
Standard Grant
CRII: CSR: From Bloom Filters to Noise Reduction Streaming Algorithms
CRII:CSR:从布隆过滤器到降噪流算法
- 批准号:
2348457 - 财政年份:2024
- 资助金额:
$ 2.18万 - 项目类别:
Standard Grant
EAGER: Search-Accelerated Markov Chain Monte Carlo Algorithms for Bayesian Neural Networks and Trillion-Dimensional Problems
EAGER:贝叶斯神经网络和万亿维问题的搜索加速马尔可夫链蒙特卡罗算法
- 批准号:
2404989 - 财政年份:2024
- 资助金额:
$ 2.18万 - 项目类别:
Standard Grant
CAREER: Efficient Algorithms for Modern Computer Architecture
职业:现代计算机架构的高效算法
- 批准号:
2339310 - 财政年份:2024
- 资助金额:
$ 2.18万 - 项目类别:
Continuing Grant
CAREER: Improving Real-world Performance of AI Biosignal Algorithms
职业:提高人工智能生物信号算法的实际性能
- 批准号:
2339669 - 财政年份:2024
- 资助金额:
$ 2.18万 - 项目类别:
Continuing Grant